病例报告：替雷利珠单抗联合安罗替尼一线治疗伴肉瘤样癌分化的转移性肾盂尿路上皮癌的显著疗效
Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation.
作者信息
Zhu Shibin, Yu Chenhao, Wang Chongwei, Ding Guoqing, Cheng Sheng
机构信息
Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
出版信息
Front Oncol. 2022 Oct 18;12:969106. doi: 10.3389/fonc.2022.969106. eCollection 2022.
BACKGROUND
Renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation is a very dangerous malignant tumor and extremely rare in clinical practice. In general, these tumors with a dismal prognosis, and there is no standard treatment.
CASE PRESENTATION
In this case, an 81-year-old male patient was diagnosed with right renal pelvic carcinoma. After an open right radical nephroureterectomy, postoperative pathological examination showed infiltrating urothelial carcinoma with sarcomatoid differentiation. Overexpression of programmed death ligand-1 by immunohistochemistry. The carcinoma recurred 4.5 months after surgery. After informed, tislelizumab combined with anlotinib were used as first-line treatment. The patients showed a clinical partial response that lasted for 20 months.
CONCLUSION
This case demonstrates the efficacy of tislelizumab combined with anlotinib in patients diagnosed with metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation. Moreover, to our knowledge, this is the first application of this treatment.
背景
伴有肉瘤样癌分化的肾盂尿路上皮癌是一种非常危险的恶性肿瘤，在临床实践中极为罕见。一般来说，这些肿瘤预后不佳，且尚无标准治疗方法。
病例介绍
在本病例中，一名81岁男性患者被诊断为右肾盂癌。在进行开放性右根治性肾输尿管切除术后，术后病理检查显示为伴有肉瘤样分化的浸润性尿路上皮癌。免疫组织化学显示程序性死亡配体-1过表达。该癌在术后4.5个月复发。在获得知情同意后，替雷利珠单抗联合安罗替尼被用作一线治疗。患者出现了持续20个月的临床部分缓解。
结论
本病例证明了替雷利珠单抗联合安罗替尼在诊断为伴有肉瘤样癌分化的转移性肾盂尿路上皮癌患者中的疗效。此外，据我们所知，这是该治疗方法的首次应用。
Zotero 插件